

TFW



PATENT
Customer No. 22,852
Attorney Docket No. 03495.0337

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Ali AMARA et al.) Group Art Unit: 1614
)
Application No.: 10/533,924 ✓) Examiner: Unknown
)
Filed: November 21, 2005) Confirmation No.: 4571
)
For: DC-SIGN BLOCKERS AND)
THEIR USES FOR PREVENTING)
OR TREATING VIRAL)
INFECTIONS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. To the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.

Copies of the U.S. patent publications are not enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 12, 2006

By: 

Kenneth J. Meyers
Reg. No. 25,146
Tel. (202) 408-4033
Fax: (202) 408-4400
Email: ken.meyers@finnegan.com

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number	10/533,924
Filing Date	November 21, 2005
First Named Inventor	Ali AMARA
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	03495.0337

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-4,522,811	06-11-1985	Eppstein et al.	
		US-4,683,195	07-28-1987	Mullis et al.	
		US-4,683,202	07-28-1987	Mullis	
		US-5,223,409	06-29-1993	Ladner et al.	
		US-5,403,484	04-04-1995	Ladner et al.	
		US-5,498,538	03-12-1996	Kay et al.	
		US-5,516,637	05-14-1996	Huang et al.	
		US-5,571,698	11-05-1996	Ladner et al.	
		US-5,625,033	04-29-1997	Kay et al.	
		US-5,658,727	08-19-1997	Barbas et al.	
		US-5,667,988	09-16-1997	Barbas et al.	
		US-6,391,567 B1	05-21-2002	Littman et al.	
		US-5,565,332 A	10-15-1996	Hoogenboom et al.	
		US-20040141968 A1	07-22-2004	Amara et al.	
		US-20040197330 A1	10-07-2004	Amara et al.	


Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		EP 1046651 A1	10/25/2000	Figdor et al.		
		WO 91/05876 A1	05/02/1991	Gehrz et al.		
		WO 00/63251	10/26/2000	KATHOLIEKE UNIVERSITEIT NIJMEGEN		
		WO 93/01820	02/04/1993	BRISTOL-MYERS SQUIBB COMPANY		
		WO 02/080851 A2	10/17/2002	THE JOHNS HOPKINS UNIVERSITY		
		WO 01/64752 A2	07/09/2001	NEW YORK UNIVERSITY		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		Desrosiers, R., "Prospects for an AIDS Vaccine," <i>Nature Medicine</i> , 10(3):221-233 (2004)	
		Feinberg et al, "AIDS Vaccine Models: Challenging Challenge Viruses," <i>Nature Medicine</i> , 9(3):207-210 (2002).	
		Greene, W., "The Brightening Future of HIV Therapeutics," <i>Nature Immunology</i> , 4(9):867-871 (2004).	
		Halary et al.; 'HUMAN CYTOMEGALOVIRUS BINDING TO DC-SIGN IS REQUIRED FOR DENDRITIC	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number		10/533,924	
		Filing Date		November 21, 2005	
		First Named Inventor		Ali AMARA	
		Art Unit		1614	
		Examiner Name		Unknown	
Sheet	2	of	2	Attorney Docket Number 03495.0337	

NON PATENT LITERATURE DOCUMENTS			
		CELL INFECTION AND TARGET CELL TRANS-INFECTION"; Immunity, Vol. 17, No. 5, pages 653-664, (2002)	
		Kwon et al.; "DC-SIGN-MEDIATED INTERNALIZATION OF HIV IS REQUIRED FOR TRANS-ENHANCEMENT OF T CELL INFECTION"; Immunity, Vol. 16, No. 1, pages 135-144, (2002)	
		MacDonald et al., "Mucosal and Parenteral Vaccination Against Acute and Latent MCMV," J. Virology, 72(1):442-451 (1998).	
		Navarro-Sanchez et al.; "DENDRITIC-CELL-SPECIFIC ICAM3-GRABBING NON-INTEGRIN IS ESSENTIAL FOR THE PRODUCTIVE INFECTION OF HUMAN DENDRITIC CELLS BY MOSQUITO-CELL-DERIVED DENGUE VIRUSES"; EMBO Reports, Vol. 4, No. 7, pages 723-728, (2003)	
		Tassaneeritthep et al.; "DC-SING (CD209) MEDIATES DENGUE VIRUS INFECTION OF HUMAN DENDRITIC CELLS"; Journal of Experimental Medicine, Vol. 197, No. 7, pages 823-829, (2003)	
		Wang et al., "Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B, J. Virology, 78(8):3965-3976 (2004).	
		Men et al., "Identification of Chimpanzee fab Fragments," Journal of Virology, 2004, 78(9): 4665-4674.	
		Brandriss et al. "LETHAL 17D YELLOW FEVER ENCEPHALITIS IN MICE", Journal of General Virology, 1986, 67:229-234.	
		Lyssen et al., "PERSPECTIVES FOR THE TREATMENT OF INFECTIONS WITH FLAVIVIRIDAE, Clinical Microbiology Reviews, 2000, 13(1):67-82.	
		Curtis, Benson M. et al., "SEQUENCE AND EXPRESSION OF A MEMBRANE-ASSOCIATED C-TYPE LECTIN THAT EXHIBITS CD4-INDEPENDENT BINDING OF HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEIN gp120," Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 8356-8360 (1992).	
		Geijtenbeek, Teunis B.H. et al., "IDENTIFICATION OF DC-SIGN, A NOVEL DENDRITIC CELL-SPECIFIC ICAM-3 RECEPTOR THAT SUPPORTS PRIMARY IMMUNE RESPONSES," Cell, Vol. 100, pp. 575-585 (2000).	
		Tailleux, Ludovic et al., "DC-SIGN IS THE MAJOR MYCOBACTERIUM TUBERCULOSIS RECEPTOR ON HUMAN DENDRITIC CELLS," The Journal of Experimental Medicine, Vol. 197, pp. 121-127 (2003).	
		Patent Application No. 10/464,531 of Oliver NEYROLLES, Oliver SCHWARTZ, Ludvic TAILLEUX, and Philippe LAGRANGE, filed June 19, 2003 (Identified by Attorney Docket No. 03495.0270).	
		Copy of Office Action dated December 28, 2004, in Application No. 10/700,507 (identified by Attorney Docket No. 03495.0301).	
		Copy of Office Action dated October 17, 2005, in Application No. 10/700,507 (identified by Attorney Docket No. 03495.0301).	
		Copy of Office Action dated December 28, 2004, in Application No. 10/700,491 (identified by Attorney Docket No. 03495.0300).	
		Copy of Office Action dated July 26, 2005, in Application No. 10/700,491 (identified by Attorney Docket No. 03495.0300).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.